Myfenax (Mycophenolate Mofetil)

Myfenax (mycophenolate mofetil) is used in immunosuppressive regimens for solid organ transplantation and selected autoimmune conditions.

• Kidney transplantation: helps prevent acute rejection and supports long‑term graft survival.
• Liver transplantation: provides maintenance immunosuppression to reduce risk of graft loss.
• Heart transplantation: used to prevent rejection episodes in heart transplant recipients.
• Lupus nephritis (off‑label): may be employed as part of therapy to control renal inflammation.

• Mycophenolate mofetil is a pro‑drug that is converted to mycophenolic acid, which selectively inhibits inosine monophosphate dehydrogenase (IMPDH). By blocking IMPDH, the synthesis of guanosine nucleotides is reduced, limiting DNA replication in activated T‑ and B‑lymphocytes. This selective suppression of lymphocyte proliferation diminishes the immune response that leads to graft rejection. The effect is reversible and primarily affects proliferating immune cells while sparing resting cells, providing targeted immunosuppression.

Mycophenolate mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, vomiting, diarrhea, or abdominal pain.
• Infections: increased susceptibility to bacterial, viral, or fungal infections.
• Hematologic changes: anemia, leukopenia, or thrombocytopenia.
• Headache: mild to moderate intensity.
• Elevated liver enzymes: transient increases in ALT or AST.

Serious or Rare Side Effects

• Severe infection: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Bone marrow suppression: profound neutropenia or pancytopenia.
• Renal toxicity: acute kidney injury or interstitial nephritis.
• Malignancy risk: increased incidence of post‑transplant lymphoproliferative disorder.
• Pregnancy complications: teratogenic effects and fetal loss.

When prescribing Myfenax, clinicians should consider several precautionary measures to minimize risks.

• Renal function: assess baseline creatinine and adjust dose in renal impairment.
• Hepatic function: monitor liver enzymes regularly during therapy.
• Infection risk: screen for latent infections (e.g., TB, hepatitis B) before initiation.
• Pregnancy: avoid use in pregnant women due to teratogenicity; use effective contraception.
• Vaccination: avoid live vaccines while on therapy.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and light.

Mycophenolate mofetil interacts with several drugs that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Antimetabolites (e.g., azathioprine): additive bone marrow suppression.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce mycophenolate levels.
• Live vaccines: may cause severe infection.

Moderate Interactions (Monitor Closely)

• Antacids containing magnesium or aluminum: may decrease absorption; separate dosing by at least 2 hours.
• Cyclosporine or tacrolimus: may increase mycophenolate exposure; monitor blood counts.
• Contraceptive hormones: possible reduced efficacy; advise additional barrier methods.